Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

High rates of overall response and MRD negativity were seen regardless of the dose patients received, said Andrew Spencer, MBBS.

Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...

In the end, all I could say is I have been there through sickness and your darkest times, and he didn’t say anything. I told ...

Co-owner of Burlington’s Finnigan’s Pub for more than 32 years was known for his work ethic, great attitude and remarkable ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report), ...

Investment analysts at StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX – Get Free Report) in a research note issued on Saturday. The brokerage set a “hold” rating on the biotechnology ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Legend Biotech (LEGN – Research Report), with a ...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.